S&P 500   3,204.96 (-0.67%)
DOW   26,772.78 (-0.36%)
S&P 500   3,204.96 (-0.67%)
DOW   26,772.78 (-0.36%)
S&P 500   3,204.96 (-0.67%)
DOW   26,772.78 (-0.36%)
S&P 500   3,204.96 (-0.67%)
DOW   26,772.78 (-0.36%)
Log in

NASDAQ:ALNYAlnylam Pharmaceuticals Stock Price, Forecast & News

$156.41
-1.61 (-1.02 %)
(As of 07/16/2020 10:09 AM ET)
Add
Compare
Today's Range
$155.12
Now: $156.41
$157.70
50-Day Range
$125.39
MA: $143.14
$162.25
52-Week Range
$69.11
Now: $156.41
$164.09
Volume1,086 shs
Average Volume1.02 million shs
Market Capitalization$18.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.86
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More
Alnylam Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$219.75 million
Book Value$12.90 per share

Profitability

Net Income$-886,120,000.00
Net Margins-310.01%

Miscellaneous

Employees1,323
Market Cap$18.04 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

How has Alnylam Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALNY shares have increased by 53.5% and is now trading at $156.41. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alnylam Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alnylam Pharmaceuticals.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Alnylam Pharmaceuticals.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($1.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.89) by $0.27. The biopharmaceutical company had revenue of $71.94 million for the quarter, compared to analysts' expectations of $90.45 million. Alnylam Pharmaceuticals had a negative return on equity of 57.63% and a negative net margin of 310.01%. The company's quarterly revenue was up 173.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.42) EPS. View Alnylam Pharmaceuticals' earnings history.

What price target have analysts set for ALNY?

18 brokers have issued 12 month target prices for Alnylam Pharmaceuticals' stock. Their forecasts range from $74.00 to $202.00. On average, they expect Alnylam Pharmaceuticals' share price to reach $153.33 in the next year. This suggests that the stock has a possible downside of 2.0%. View analysts' price targets for Alnylam Pharmaceuticals.

Has Alnylam Pharmaceuticals been receiving favorable news coverage?

News articles about ALNY stock have trended positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news about Alnylam Pharmaceuticals.

Who are some of Alnylam Pharmaceuticals' key competitors?

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), Opko Health (OPK), AbbVie (ABBV) and Vertex Pharmaceuticals (VRTX).

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the following people:
  • Dr. John M. Maraganore, CEO & Exec. Director (Age 56)
  • Mr. Barry E. Greene, Pres (Age 56)
  • Mr. Manmeet Singh Soni, Sr. VP, CFO & Principal Accounting Officer (Age 41)
  • Dr. Yvonne Greenstreet MBChB, MBA, Exec. VP & COO (Age 56)
  • Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56)

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.03%), International Biotechnology Trust PLC (0.03%), State of Alaska Department of Revenue (0.02%), DNB Asset Management AS (0.01%), IFM Investors Pty Ltd (0.01%) and New England Research & Management Inc. (0.00%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View institutional ownership trends for Alnylam Pharmaceuticals.

Which institutional investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet. View insider buying and selling activity for Alnylam Pharmaceuticals.

Which institutional investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., State of Alaska Department of Revenue, International Biotechnology Trust PLC, New England Research & Management Inc., DNB Asset Management AS, Sanders Morris Harris LLC, Exchange Traded Concepts LLC, and IBM Retirement Fund. View insider buying and selling activity for Alnylam Pharmaceuticals.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $156.41.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $18.04 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,323 workers across the globe.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.